Investigational Drug for the treatment of Decompensated Cirrhosis

Trial ID:
Catherine Frenette, MD
This study is evaluating how safe and effective the investigational drug Emricasan may be in delaying or improving survival for patients with Decompensated NASH cirrhosis. Participation will last up to 48 weeks and requires study visits every 4 weeks.

Inclusion Criteria

  • Be 18 years or older
  • Have been diagnosed with cirrhosis due to NASH confirmed by liver biopsy

Exclusion Criteria

  • Have evidence of severe decompensation as determined by your doctor
  • Currently be taking a blood thinning medication
  • Have unstable diabetes
  • Have had bariatric within 1 year
  • Be pregnant or planning a pregnancy

Additional Info

  • Emricasan may help to block an enzyme that plays a role in the process that causes liver scarring and damage. Patients will be randomized to receive either 5mg emricasan, 25mg emricasan, or a matching placebo. Study medication will be taken twice daily in conjunction with local standard of care.

Contact Info:

  • Shannon Cyhan